Analysts Set Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Target Price at $42.60

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) has received an average rating of “Moderate Buy” from the five ratings firms that are currently covering the stock, MarketBeat reports. Two research analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $42.60.

A number of research analysts recently commented on COLL shares. Piper Sandler restated a “neutral” rating and issued a $37.00 price target on shares of Collegium Pharmaceutical in a research report on Friday, October 11th. HC Wainwright raised their target price on shares of Collegium Pharmaceutical from $47.00 to $50.00 and gave the company a “buy” rating in a report on Thursday, September 5th. Finally, StockNews.com cut shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, October 23rd.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of COLL. GAMMA Investing LLC grew its holdings in shares of Collegium Pharmaceutical by 124.5% during the 3rd quarter. GAMMA Investing LLC now owns 1,428 shares of the specialty pharmaceutical company’s stock valued at $55,000 after purchasing an additional 792 shares during the last quarter. CWM LLC grew its stake in shares of Collegium Pharmaceutical by 97.5% during the third quarter. CWM LLC now owns 1,491 shares of the specialty pharmaceutical company’s stock worth $58,000 after buying an additional 736 shares during the last quarter. nVerses Capital LLC grew its stake in shares of Collegium Pharmaceutical by 1,600.0% during the second quarter. nVerses Capital LLC now owns 1,700 shares of the specialty pharmaceutical company’s stock worth $55,000 after buying an additional 1,600 shares during the last quarter. TD Private Client Wealth LLC increased its holdings in shares of Collegium Pharmaceutical by 39.5% during the third quarter. TD Private Client Wealth LLC now owns 1,707 shares of the specialty pharmaceutical company’s stock worth $66,000 after buying an additional 483 shares in the last quarter. Finally, Virtus Fund Advisers LLC bought a new position in shares of Collegium Pharmaceutical in the 3rd quarter valued at $72,000.

Collegium Pharmaceutical Price Performance

Collegium Pharmaceutical stock opened at $29.15 on Thursday. The firm has a market cap of $940.09 million, a PE ratio of 12.56 and a beta of 0.80. The company has a debt-to-equity ratio of 3.43, a current ratio of 0.97 and a quick ratio of 0.88. The stock’s fifty day moving average price is $32.30 and its two-hundred day moving average price is $34.30. Collegium Pharmaceutical has a one year low of $28.97 and a one year high of $42.29.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.